Claim audit
Patient-facing claims and their support.
This page tracks high-risk claims, unresolved claims, and claims that need reviewer attention. It is part of the safety system.
supported
approval
Tunlametinib / HL-085 has China NMPA conditional approval in the source-cited NRAS-mutant advanced melanoma context after anti-PD-1/PD-L1 failure.
risk: highpatient-facingreviewer needed
supported
mechanism
Tunlametinib / HL-085 is described as a selective MEK1/2 inhibitor.
risk: mediumpatient-facing
unresolved
uncertainty
The exact tunlametinib plus nivolumab melanoma trial/publication has not been found and must remain an unresolved lived-context lead.
risk: highpatient-facingreviewer needed
supported
patient-safety
A trial listing match does not mean the trial fits.
risk: highpatient-facing
supported
approval
Lifileucel has FDA accelerated approval in the source-cited unresectable or metastatic melanoma context.
risk: highpatient-facingreviewer needed